BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer 2020;126:1640-50. [PMID: 31913498 DOI: 10.1002/cncr.32682] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Pozzi S, Bari A, Pecherstorfer M, Vallet S. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers (Basel) 2021;13:4978. [PMID: 34638462 DOI: 10.3390/cancers13194978] [Reference Citation Analysis]
2 Dave HM, Khorana AA. The guidelines they are a changin'. Eur J Intern Med 2020;74:5-7. [PMID: 32094020 DOI: 10.1016/j.ejim.2020.02.024] [Reference Citation Analysis]
3 Gonzalez-Porras JR, Mateo J, Gonzalez-Calle V, Marco P, Garcia-Gutierrez V, Reverter JC, Lecumberri R. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH. Clin Transl Oncol 2021. [PMID: 34850351 DOI: 10.1007/s12094-021-02735-1] [Reference Citation Analysis]
4 Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol 2020;95:672-90. [PMID: 32086970 DOI: 10.1002/ajh.25764] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
5 Santoro M, Romano A, Mancuso S, Siragusa S, DI Raimondo F, Martinelli G, Cerchione C. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Med 2021;63:1-6. [PMID: 32955183 DOI: 10.23736/S0031-0808.20.04133-6] [Reference Citation Analysis]
6 Calafiore V, Giamporcaro S, Conticello C, Romano A, Parisi M, Giuffrida G, Tibullo D, Di Raimondo F, Signorelli SS. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. J Clin Med 2020;9:E2876. [PMID: 32899553 DOI: 10.3390/jcm9092876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, Usmani SZ. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens. Clin Lymphoma Myeloma Leuk 2021;21:188-198.e2. [PMID: 33339769 DOI: 10.1016/j.clml.2020.11.015] [Reference Citation Analysis]